KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Long-Term Deferred Tax (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Long-Term Deferred Tax for 6 consecutive years, with $57.1 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax fell 26.0% to $57.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.1 million through Dec 2025, down 26.0% year-over-year, with the annual reading at $57.1 million for FY2025, 26.0% down from the prior year.
  • Long-Term Deferred Tax hit $57.1 million in Q4 2025 for GoodRx Holdings, down from $69.1 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $77.2 million in Q4 2024 to a low of $13.0 million in Q2 2021.
  • Historically, Long-Term Deferred Tax has averaged $58.0 million across 4 years, with a median of $65.3 million in 2023.
  • Biggest five-year swings in Long-Term Deferred Tax: skyrocketed 2616.3% in 2021 and later decreased 26.0% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $45.8 million in 2021, then soared by 42.43% to $65.3 million in 2023, then grew by 18.25% to $77.2 million in 2024, then decreased by 26.0% to $57.1 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for GDRX at $57.1 million in Q4 2025, $69.1 million in Q3 2025, and $77.2 million in Q2 2025.